Literature DB >> 2791487

In vitro activity of minocycline and rifampin against staphylococci.

J Segreti1, L C Gvazdinskas, G M Trenholme.   

Abstract

We tested the in vitro inhibitory and bactericidal activity of minocycline against 26 methicillin-susceptible Staphylococcus aureus, 24 methicillin-resistant S. aureus, 1 methicillin-susceptible coagulase-negative staphylococci, and 33 methicillin-resistant coagulase-negative staphylococci. Minocycline and rifampin had MIC90 results in the susceptible range, but MBCs were markedly elevated for minocycline alone (MBC50 greater than 32 micrograms/ml). The combination of minocycline and rifampin was synergistic for 30% of the isolates with the highest rates of synergy being against methicillin-resistant isolates.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2791487     DOI: 10.1016/0732-8893(89)90022-9

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  9 in total

Review 1.  Antimicrobial susceptibility of coagulase-negative staphylococci.

Authors:  G L Archer; M W Climo
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

2.  Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.

Authors:  S L Kang; M J Rybak; B J McGrath; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

3.  Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus.

Authors:  D P Nicolau; C D Freeman; C H Nightingale; C J Coe; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

4.  Antibiotics and prevention of microbial colonization of catheters.

Authors:  I Raad; R Darouiche; R Hachem; M Sacilowski; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

Review 5.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

6.  Antibiotic penetration of and bactericidal activity within endothelial cells.

Authors:  R O Darouiche; R J Hamill
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 7.  Penile prosthesis coating and the reduction of postoperative infection.

Authors:  Robert Abouassaly; Drogo K Montague
Journal:  Curr Urol Rep       Date:  2004-12       Impact factor: 2.862

Review 8.  New horizon for infection prevention technology and implantable device.

Authors:  Yusuke Kondo; Marehiko Ueda; Yoshio Kobayashi; Joerg O Schwab
Journal:  J Arrhythm       Date:  2016-03-19

9.  Antimicrobial-impregnated central venous catheters for preventing neonatal bloodstream infection: the PREVAIL RCT.

Authors:  Ruth Gilbert; Michaela Brown; Rita Faria; Caroline Fraser; Chloe Donohue; Naomi Rainford; Alessandro Grosso; Ajay K Sinha; Jon Dorling; Jim Gray; Berit Muller-Pebody; Katie Harron; Tracy Moitt; William McGuire; Laura Bojke; Carrol Gamble; Sam J Oddie
Journal:  Health Technol Assess       Date:  2020-11       Impact factor: 4.106

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.